Cipla rose 2.31% to Rs 665.45 at 11:21 IST on BSE after consolidated net profit fell 0.4% to Rs 259.66 crore on 20.8% rise in total income to Rs 3153.89 crore in Q4 March 2015 over Q4 March 2014.
The result was announced after market hours on Friday, 29 May 2015.
Meanwhile, the S&P BSE Sensex was up 96.15 points or 0.35% at 27,924.59
On BSE, so far 1.51 lakh shares were traded in the counter as against average daily volume of 1.91 lakh shares in the past one quarter.
The stock hit a high of Rs 672.60 and a low of Rs 645 so far during the day. The stock had hit a record high of Rs 752.45 on 10 March 2015. The stock had hit a 52-week low of Rs 368.70 on 30 May 2014.
The large-cap company has equity capital of Rs 160.59 crore. Face value per share is Rs 2.
Cipla said that the current year figures included the relevant results of the company's subsidiaries from the date they became subsidiary of the company and therefore the corresponding figures for the previous period are not comparable.
Cipla's earnings before interest, taxation, depreciation and amortization (EBITDA) grew by 24% to Rs 508 crore in Q4 March 2015 over Q4 March 2014.
Cipla's domestic sales grew by 20.7% to Rs 1086 crore in Q4 March 2015 over Q4 March 2014 largely on account of growth in Respiratory, Anti-infectives, Cardiac and Gastro Intestinal therapies.
Cipla's exports of formulations increased by 29.7% to Rs 1690 crore in Q4 March 2015 over Q4 March 2014. Exports of Active Pharmaceutical Ingredients (APIs) declined 14.58% to Rs 205 crore in Q4 March 2015 over Q4 March 2014.
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.
Powered by Capital Market - Live News
